[go: up one dir, main page]

ATE290880T1 - Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält - Google Patents

Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Info

Publication number
ATE290880T1
ATE290880T1 AT01936440T AT01936440T ATE290880T1 AT E290880 T1 ATE290880 T1 AT E290880T1 AT 01936440 T AT01936440 T AT 01936440T AT 01936440 T AT01936440 T AT 01936440T AT E290880 T1 ATE290880 T1 AT E290880T1
Authority
AT
Austria
Prior art keywords
inosine
cytosine
composition containing
polycationic peptide
antigen composition
Prior art date
Application number
AT01936440T
Other languages
English (en)
Inventor
Alena Egyed
Karen Lingnau
Frank Mattner
Michael Buschle
Walter Schmidt
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of ATE290880T1 publication Critical patent/ATE290880T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01936440T 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält ATE290880T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
PCT/EP2001/006437 WO2001093903A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine

Publications (1)

Publication Number Publication Date
ATE290880T1 true ATE290880T1 (de) 2005-04-15

Family

ID=3683921

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung

Country Status (7)

Country Link
US (2) US7148191B2 (de)
EP (1) EP1286695B1 (de)
AT (2) AT410173B (de)
AU (1) AU2001262345A1 (de)
DE (1) DE60109443T2 (de)
WO (1) WO2001093903A1 (de)
ZA (1) ZA200209479B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4864264B2 (ja) * 1999-12-22 2012-02-01 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
WO2001093905A1 (en) * 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
AU2001297693A1 (en) * 2000-12-08 2002-09-12 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
ATE322288T1 (de) 2001-01-03 2006-04-15 Epitopix Llc Zusammensetzungen zur immunisierung sowie deren verwendung
EP1347776A2 (de) * 2001-01-05 2003-10-01 Intercell Biomedizinische Forschungs- und Entwicklungs AG Gebrauch von polykationen als entzündungshemmende mittel
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
AU2002358616A1 (en) * 2001-12-07 2003-06-17 Intercell Ag Immunostimulatory oligodeoxynucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
JP2005527506A (ja) * 2002-02-28 2005-09-15 インターツェル・アクチェンゲゼルシャフト リガンドｅ．ｇ．ｔ細胞エピトープの単離方法
AU2003243161A1 (en) * 2002-04-24 2003-11-10 The Regents Of The University Of California Methods for stimulating tlr/irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses
ATE535231T1 (de) * 2002-07-03 2011-12-15 Oncovir Inc Verfahren zur herstellung von poly-iclc und seine verwendung
CA2484941A1 (en) * 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
US7378234B2 (en) * 2002-09-13 2008-05-27 Intercell Ag Method for isolating hepatitis C virus peptides
CA2502414A1 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
WO2004055041A2 (en) * 2002-12-13 2004-07-01 Case Western Reserve University Defensin-inducing peptides from fusobacterium
EP2287311A1 (de) 2003-03-04 2011-02-23 Intercell AG Streptococcus-pyogenes-Antigene
US7704514B2 (en) * 2003-03-24 2010-04-27 Intercell Ag Vaccines
CN101214375B (zh) * 2003-03-24 2011-04-06 英特塞尔股份公司 改进的疫苗
US7628994B2 (en) 2003-03-31 2009-12-08 Intercell Ag S. epidermidis antigens
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
AU2004235952A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens I + II
EP2267006A1 (de) 2003-05-30 2010-12-29 Intercell AG Enterokokken-Antigene
NZ582566A (en) * 2003-09-19 2010-11-26 Epitopix Llc Metal regulated polypeptides and methods of use from campylobacter spp.
ES2327432T3 (es) * 2004-10-29 2009-10-29 Intercell Ag Vacunas contra el vhc para pacientes con vhc cronica.
CA2597263C (en) * 2005-02-14 2017-01-17 Epitopix, Llc Polypeptides from staphylococcus aureus and methods of use
CA2654271A1 (en) 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
EP2292646A3 (de) 2006-07-07 2011-06-08 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
EP2059526A2 (de) 2006-09-15 2009-05-20 Intercell AG Borrelia-antigene
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
WO2008084072A2 (en) 2007-01-12 2008-07-17 Intercell Ag Protective proteins of s. agalactiae, combinations thereof and methods of using the same
EP2125853A1 (de) * 2007-03-07 2009-12-02 Nventa Biopharmaceuticals Corporation Doppelsträngige lna-zusammensetzungen
EP2360177A1 (de) 2007-05-02 2011-08-24 Intercell AG Klebsiella-Antigene
WO2008145400A2 (en) 2007-05-31 2008-12-04 Medigene Ag Mutated structural protein of a parvovirus
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
EP2511291A3 (de) 2007-06-18 2012-11-07 Intercell AG Chlamydia-Antigene
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20110038888A1 (en) * 2008-01-10 2011-02-17 Peter Emtage Adjuvant compositions comprising poly-ic and a cationic polymer
EP2265634A2 (de) 2008-03-17 2010-12-29 Intercell AG Peptide schutzmittel gegen s. pneumoniae und zusammensetzungen, verfahren und anwendung im zusammenhang damit
US20110070298A1 (en) 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
LT3056214T (lt) 2008-06-27 2019-06-10 Zoetis Services Llc Naujos adjuvantų kompozicijos
WO2010089340A2 (en) 2009-02-05 2010-08-12 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (de) 2009-02-13 2012-01-18 Intercell AG Nicht typisierbare haemophilus influenza-antigene
MX339461B (es) 2009-03-23 2016-05-27 Epitopix Llc Polipeptidos y composiciones inmunizantes que contienen polipeptidos grampositivos y metodos de uso.
EP2308896A1 (de) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
JP2013507115A (ja) 2009-10-09 2013-03-04 サノフイ 「終末糖化産物受容体」への結合のためのポリペプチド、さらにはそれを含む組成物及び方法
EP2319871A1 (de) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
AR082925A1 (es) 2010-09-08 2013-01-16 Medigene Ag Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
CN109675029A (zh) 2013-09-19 2019-04-26 硕腾服务有限责任公司 油基佐剂
ES2950822T3 (es) 2015-01-16 2023-10-13 Zoetis Services Llc Vacuna contra la enfermedad de fiebre aftosa
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
EP3527223A1 (de) 2018-02-16 2019-08-21 2A Pharma AB Mutiertes parvovirus-strukturprotein
AU2019220386A1 (en) 2018-02-16 2020-08-20 2A Pharma Ab Parvovirus structural protein for the treatment of autoimmune diseases
EP3972639A1 (de) 2019-05-20 2022-03-30 Valneva SE Subunit-impfstoff zur behandlung oder vorbeugung einer atemwegsinfektion
US12214028B2 (en) 2019-05-31 2025-02-04 Universidad De Chile Immunogenic formulation that induces protection against shiga toxin-producing Escherichia coli (STEC)
WO2022074061A1 (en) 2020-10-07 2022-04-14 Valneva Sweden Ab Cholera vaccine formulation
AU2022255923A1 (en) 2021-04-09 2023-08-31 Valneva Se Human metapneumo virus vaccine
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6801650D0 (pt) * 1968-08-20 1973-03-07 R Maes Processo para preparacao de complexos geradores de interferon
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
WO1998003532A1 (en) * 1996-07-24 1998-01-29 Hanna Michelle M Base-protected nucleotide analogs with protected thiol groups
WO2001078767A2 (en) * 2000-04-14 2001-10-25 Cistem Biotechnologies Gmbh Pharmaceutical preparations comprising modified peptides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung

Also Published As

Publication number Publication date
DE60109443D1 (de) 2005-04-21
US20070218073A1 (en) 2007-09-20
WO2001093903A1 (en) 2001-12-13
EP1286695A1 (de) 2003-03-05
ZA200209479B (en) 2003-11-21
AU2001262345A1 (en) 2001-12-17
US7148191B2 (en) 2006-12-12
AT410173B (de) 2003-02-25
DE60109443T2 (de) 2006-04-13
EP1286695B1 (de) 2005-03-16
ATA10002000A (de) 2002-07-15
US20030162738A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
ATE290880T1 (de) Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE500323T1 (de) Subtilisin-variante
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
DE60037450D1 (de) Funf-helix protein
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
ATE247484T1 (de) Von der telomerase abgeleitete antigene peptide
NI200800193A (es) Anticuerpos humanos anti-il-23, composiciones, métodos y usos.
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
TR199900267T2 (xx) GnRH-L�kotoksin kimeralar�.
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
ATE347600T1 (de) Gruppe b-streptococcus antigene
EP1568373A3 (de) Induzierung von zellulärer Immunantwort auf HER2/neu mit Hilfe von Peptid- und Nukleinsäurezubereitungen
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
IL142905A0 (en) Functional antagonists of hedgehog activity
ATE460176T1 (de) Mikrosomvakzin
DE69734974D1 (de) Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
DE69938725D1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
PT1290160E (pt) Polipeptideos pellino humanos
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1286695

Country of ref document: EP